AdvanTIG-301: Ociperlimab Plus Tislelizumab Versus Durvalumab After Concomitant Chemo/Radiotherapy
Condition: Non-Small Cell Lung Cancer
Sponsor: BeiGene, Ltd.
Full Title
Protocol BGB-A317-A1217-301: A Phase 3, Randomized, Open-Label Study to Compare Ociperlimab (BGB-A1217) Plus Tislelizumab (BGB-A317) Versus Durvalumab in Patients With Locally Advanced, Unresectable, PD-L1-Selected Non-Small Cell Lung Cancer Whose Disease Has Not Progressed After Concurrent Chemoradiotherapy
Eligibility
Patients with stage III, unresectable non-small cell lung cancer who have received platinum-based chemotherapy concomitantly with radiation therapy and who have not experienced disease progression after the completion of chemo/radiotherapy.
Contact
For more information you may contact the Research Department through the NYCBS HALO Messaging Center or call directly: 631-675-5075.
